Trading: Short Peloton, the one-trick pony

Exercise-bike maker Peloton faces stiff competition and is hugely overpriced, says Matthew Partridge.

The crisis has given many technology stocks a big boost. One of the biggest turnarounds has occurred at Peloton (Nasdaq: PTON), which makes expensive exercise bikes that come with streamed workout lessons. In late 2019 a disastrous advertising campaign had left it widely mocked, with many speculating that it was only the latest in a string of overhyped stocks. However, the pandemic and the subsequent closure of gyms has created huge demand for home-exercise equipment, propelling Peloton’s stock from $25 at the start of the year to a peak of $68.

Peloton may have done well during the crisis, with the company’s management talking about “holiday-like demand”, but its future looks more uncertain, especially with countries around the world (including the UK) starting to reopen gyms as part of a wider effort to stimulate the economy. Of course, many people may still be reluctant to visit the gym, or feel uncomfortable with the social-distancing requirements still in place. However, the rapid progression of multiple vaccine trials around the world means that there is a realistic prospect of a return to pre-crisis normality by the end of the year, which could mean that sales growth slows, or even reverses.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up
Latest Videos FromMoneyWeek
Dr Matthew Partridge
MoneyWeek Shares editor